Compare Novavax Inc (NVAX) vs AT&T Inc. (T) Price & Performance

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.

AT&T (T) trades at $24.885, up 1.88% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 8.08 and net income margin of 16.94%. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while cash flow improved to $15.12B in 2025.

The stock offers value with a 4%+ dividend yield and analyst consensus price target of $27.61, but faces risks from high debt and competitive pressures. Upside depends on execution in fiber and wireless, while sentiment is mixed amid dividend sustainability concerns.